News

Aptose Biosciences and Hanmi Pharmaceutical: A New Era Begins

Aptose Biosciences and Hanmi Pharmaceutical: A New Era Begins

Aptose Biosciences Enters Acquisition Agreement with Hanmi Pharmaceutical

Aptose Biosciences Inc. (TSX: APS, OTC: APTOF) has announced a significant arrangement agreement with Hanmi Pharmaceutical Co. Ltd. that will see all issued common shares of Aptose, not already held by Hanmi or its affiliates, acquired by them. This move marks a pivotal moment in the operations of Aptose, propelling their oncology endeavors into a new chapter.

Details of the Arrangement Agreement

The agreement involves not only a strategic acquisition but also the financial backing that Hanmi has provided over recent periods. They own approximately 19.93% of Aptose's common shares and have supported the company with over US$30 million in debt facilities for the development of its lead compound, tuspetinib (TUS).

Financial Implications for Shareholders

Upon the completion of the acquisition, shareholders of Aptose, excluding the Hanmi affiliates, will receive a cash amount of C$2.41 per common share. This figure reflects a substantial premium of 28% compared to Aptose's 30-day volume-weighted average price (VWAP) of C$1.88. Therefore, the offer presents a lucrative opportunity for minority shareholders.

Future Developments with Tuspetinib

William G. Rice, the Chairman, President, and CEO of Aptose expressed his enthusiasm about the agreement, stating it provides not only a premium for shareholders but also ensures continuous development of TUS combined with existing treatments for acute myeloid leukemia (AML). Early clinical trials showcased promising results, and this acquisition could enhance further research and patient outcomes significantly.

Hanmi's Strategic Expansion into North America

The acquisition signifies Hanmi’s first substantial entry into the North American biopharmaceutical market. Jae-Hyun Park from Hanmi emphasized the importance of supporting the ongoing development of tuspetinib, aiming to leverage strong data for future clinical expansions.

Transaction Logistics and Requirements

Transitioning Aptose from a corporation established under the Canada Business Corporations Act to one governed by the Business Corporations Act (Alberta) will continue under the framework of this agreement. Shareholder approval, as well as court sanctions, are crucial components for the finalization of this acquisition.

The shareholders of Aptose are expected to approve the agreement by voting at a special meeting set to occur by January 16, 2026. This approval will include a two-thirds majority requirement, excluding votes from Hanmi affiliates.

Evaluating the Fairness of the Transaction

To ensure that the arrangement is in the best interests of Aptose shareholders, Locust Walk Securities, LLC was appointed to conduct a formal valuation. Their assessment placed the fair market value of Aptose shares within a range of C$1.00 to C$5.23, highlighting the offer as fair from a financial standpoint.

The Role of the Aptose Board

Both the Special Committee and the Board of Directors of Aptose have unanimously approved the proposed arrangement, reflecting their confidence in the benefits this acquisition will bring to the company and its shareholders.

About Tuspetinib and its Impact on AML Treatment

The ongoing TUSCANY Phase 1/2 study is a crucial component of Aptose's research into its lead compound, tuspetinib. This therapy focuses on providing effective treatment options for newly diagnosed AML patients who are ineligible for induction chemotherapy. The outcomes to date indicate a high response rate, offering hope for patients facing difficult diagnoses.

Background on Hanmi Pharmaceutical

Hanmi Pharmaceutical, founded in 1973 in South Korea, has established itself as a key player in biopharmaceuticals, focusing on innovative cancer therapies and other diseases. With geographic expansion into North America, the company aims to enhance its collaborative partnerships and increase its global footprint.

Contact Information for Aptose Biosciences Inc.

For more information regarding this acquisition and future developments, you can reach Aptose as follows:

Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com

Frequently Asked Questions

What is the acquisition deal between Aptose and Hanmi?

Aptose is set to be acquired by Hanmi Pharmaceutical, with shareholders receiving C$2.41 for each share owned, marking a premium over recent trading prices.

When will the shareholder meeting occur?

The special meeting for Aptose's shareholders is scheduled no later than January 16, 2026, to vote on the acquisition agreement.

What is tuspetinib, and why is it significant?

Tuspetinib (TUS) is a key drug in Aptose's pipeline, aimed at treating acute myeloid leukemia. Its clinical trials have shown promising safety and efficacy.

Who conducted the valuation of Aptose's shares?

Locust Walk Securities was retained to provide an independent valuation of Aptose's shares to ensure fairness in the acquisition offer.

What is Hanmi's strategy in North America?

Hanmi aims to establish a strategic presence in North America through the acquisition, enabling future partnerships and clinical development opportunities.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 107

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 73

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

Cathie Wood's Bold Investment in BitMine's Ethereum Strategy

Updated Category News Views 200

ARK Invest's Strategic Move ARK Invest, under the dynamic leadership of Cathie Wood, has taken a significant step by investing in BitMine Immersion Technologies Inc. The firm acquired nearly 4.8 million shares of BitMine, valued at an impressive $182 million through multiple ARK funds. Focus on Ethereum Acquisition This investment reflects BitMine's ambitious plan to...

Continue Reading
23andMe Advances Chapter 11 Plans with Court Approvals

Updated Category News Views 421

23andMe Secures Court Approval in Chapter 11 Process In a significant development, 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), recognized for its innovative approach in genetics and biotechnology, has received critical approvals from a Bankruptcy Court related to its Chapter 11 petitions. These petitions were filed, propelling the Company into a...

Continue Reading
Insights into Archer Aviation's Stock and Market Movements

Updated Category News Views 190

Understanding Archer Aviation's Stock Dynamics In a notable shift, investors with significant capital are displaying a bullish outlook on Archer Aviation. This uptrend is primarily highlighted by the option trading activities surrounding the company. Recent Option Trading Insights The latest data reveals that there have been 20 trades observed within Archer Aviation's...

Continue Reading
PACT Capital Partners Sets New Standards in Investment Strategies

Updated Category News Views 471

PACT Capital Partners Launches as an Independent Investment Firm PACT Capital LLC, known as PACT Capital Partners, has officially launched as a pioneering independent investment firm focused on empowering middle-market alternative asset managers. With significant backing from major players, the firm aims to carve a niche in the competitive investment landscape. Strategic...

Continue Reading
Bakery Mixes Forecast 2026-2036: Growth and Trends

Updated Category News Views 61

Standardization Taking Center Stage in Bakery Mixes Imagine a bustling bakery floor, with the smell of fresh bread wafting through the air. Yet behind the scenes lies a streamlined operation driven by pre-formulated mixes, which is exactly where the global bakery mixes market finds its muscle these days. Valued at $6.5 billion in 2025, the market has its sights set on...

Continue Reading